RAB5B

Across TCGA pan-cancer cohorts, RAB5B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAB5B data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RAB5B mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RAB5B expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

LUAD, GBM, and PDAC are the cancer types where RAB5B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.207	0.705	.001	17	view →
GBM	DFS	Quartile	All	0.497	0.240	.013	14	view →
PDAC	OS	Median	IV	0.381	0.951	.006	12	view →
CCRCC	OS	Quartile	All	1.000	0.451	.012	6	view →
UCEC	DFS	Tertile	All	0.910	1.000	.040	4	view →
LSCC	DFS	Median	All	0.992	0.885	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAB5B–LUAD (OS)

Open the LUAD breakdown →